The study revealed that the inhibition of YAP1 by CA3 increases DUSP1, activation of the EGFR/MAPK pathway, and induction of autophagy may enhance the efficacy of third-generation EGFR-TKI treatments for NSCLC patients.100. The gene discussed is YAP1; the disease is non-small cell lung carcinoma.